SINGAPORE -- Biosensors International Group, Ltd. has entered into a strategic distribution agreement with Cardinal Health. Through this distribution agreement, Biosensors will significantly increase the market coverage and penetration of its leading family of Drug Eluting Stents (DES) which include the innovative BioFreedom™ polymer-free drug coated stent (DCS) clinically proven to be effective in the treatment of High Bleeding Risk (HBR) patients; the market-proven BioMatrix NeoFlex™ and the recently introduced BioMatrix Alpha™, a cobalt chromium DES with an abluminal bio-absorbable coating and the proprietary BA-9 Biolimus™ drug; and Chroma™, a cobalt-chromium bare metal stent (BMS).
The agreement will initially enable Cordis, Cardinal Health's interventional vascular business, to sell Biosensors family of DES in various European countries, Australia and New Zealand. Over time, Biosensors and Cardinal Health will partner to further leverage their respective distribution capabilities in select regions.
Last year, Biosensors announced the exciting results of the LEADERS FREE clinical trial which confirmed the safety and efficacy of BioFreedom™ in one of the largest ever double-blind, randomized, clinical trials involving a DES. The data, which were published in the New England Journal of Medicine as the world's first prospective, double-blind, randomized clinical trial focusing on patients at high bleeding risk, demonstrated superior safety and efficacy for BioFreedom™ as compared to an uncoated BMS in patients who could tolerate only one month of dual anti-platelet therapy (DAPT)3.The LEADERS FREE trial included 2,466 patients across 68 sites in 20 countries in Europe, Asia, Australia and Canada and used the shortest course of DAPT ever used with an active stent.
For more information, please visit http://www.biosensors.com